South San Francisco IPOs

10 companies in South San Francisco tracking toward an IPO in 2026.

Allogene Therapeutics logo

Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer treatment. The company's approach uses engineered cells from healthy donors rather than patients' own cells, potentially enabling off-the-shelf treatments. Investors track Allogene's clinical progress in the competitive CAR T therapy market.

PublicCell Therapy Biotechnology
Freenome logo

Freenome

Freenome is a biotechnology company developing blood-based tests for early cancer detection using artificial intelligence and genomics. The company's platform aims to detect cancer before symptoms appear, which could significantly improve patient outcomes and represents a large market opportunity in precision medicine.

No IPO AnnouncedBiotechnology
Insitro logo

Insitro

Insitro is a drug discovery company that uses machine learning and data science to identify new medicines and predict their effectiveness. The company combines high-throughput biology with AI to accelerate pharmaceutical development and reduce the traditional costs and timelines associated with bringing new drugs to market.

No IPO AnnouncedAI Drug Discovery
Mammoth Biosciences logo

Mammoth Biosciences

Mammoth Biosciences is a biotechnology company that develops CRISPR-based diagnostic and therapeutic platforms. The company focuses on creating next-generation gene editing tools and diagnostic tests using its proprietary CRISPR technology, with applications in healthcare, agriculture, and industrial biotechnology. Investors are interested in Mammoth Biosciences due to the transformative potential of CRISPR technology and the company's innovative approach to gene editing applications.

No IPO AnnouncedBiotechnology
Plenty logo

Plenty

Plenty operates indoor vertical farms using advanced LED lighting and automation technology to grow fresh produce near urban centers year-round. The company has attracted significant investor interest for its approach to sustainable agriculture and local food production, potentially addressing food security and supply chain challenges.

No IPO AnnouncedVertical Farming & AgTech
Tizona Therapeutics logo

Tizona Therapeutics

Tizona Therapeutics is a biotechnology company focused on developing immunotherapy treatments for cancer patients. The company specializes in creating novel therapeutic approaches that harness the immune system to fight various types of cancer.

No IPO AnnouncedBiotechnology
Twist Bioscience logo

Twist Bioscience

Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using its proprietary silicon platform. The company's technology enables the production of high-quality synthetic DNA at scale for applications in healthcare, agriculture, chemicals, and data storage. Twist's synthetic DNA is used by researchers, biotechnology companies, and pharmaceutical companies for various applications including drug discovery and development.

PublicSynthetic Biology
Veracyte logo

Veracyte

Veracyte is a genomic diagnostics company that develops molecular diagnostic tests to help guide cancer treatment decisions. The company's tests analyze gene expression patterns to provide information about cancer prognosis and treatment options. It focuses on areas like thyroid, lung, breast, and other cancers, providing valuable diagnostic insights for physicians and patients.

PublicGenomic Diagnostics
Verily logo

Verily

Verily Life Sciences is Alphabet's life sciences subsidiary focused on using technology and data science to improve health outcomes. The company develops digital health tools, conducts clinical research, and creates medical devices and software platforms. Investors are interested in its potential to revolutionize healthcare through data analytics and precision medicine.

No IPO AnnouncedDigital Health Technology
Xaira Therapeutics logo

Xaira Therapeutics

Xaira Therapeutics is an AI-driven drug discovery company that uses machine learning and computational biology to accelerate pharmaceutical development. The company has attracted significant attention from investors due to its substantial funding and focus on applying artificial intelligence to streamline the traditionally lengthy and expensive drug development process.

No IPO AnnouncedBiotechnology

Track South San Francisco IPOs

Get daily alerts when companies in South San Francisco file S-1s or announce IPO dates.

Get IPO Alerts